Skip to content
drillr.ai
Sign up

ABVX

Abivax SA

NASDAQ · Healthcare · Biotechnology · FR

$105.04
−1.82%
Ask drillr

  • Sep 14, 2026, 08:55 UTC

    Abivax SA is scheduled to release its first-half earnings report after the closing bell on Monday, Sept. 21.

    Source:

  • Sep 10, 2026, 07:47 UTC

    Abivax stock rose 3.0% to €104.2 on Euronext Paris on September 10, 2026.

    Source:

  • Jul 16, 2026, 14:25 UTC

    Abivax raised $920 million in a capital raise to fund operations into Q4 2029.

    Source:

  • Jul 10, 2026, 10:10 UTC

    Abivax raised $920 million in a funding round to finance a solo U.S. launch of its bowel disease drug.

    Source:

  • Jul 1, 2026, 05:30 UTC

    Abivax SA requested a temporary halt of trading of its ordinary shares on Euronext Paris, effective from market opening at 9:00 a.m. on July 1, 2026.

    Source:

  • Jul 1, 2026, 04:56 UTC

    Abivax shares surged over 38% on June 30, 2026, after new Phase 3 data eased cancer-safety fears.

    Source:

  • Jun 30, 2026, 20:45 UTC

    Abivax SA launched an underwritten public offering of approximately $600 million of its American Depositary Shares in the United States.

    Source:

  • Jun 30, 2026, 17:16 UTC

    Abivax SA released updated safety data from its late-stage ulcerative colitis program for obefazimod.

    Source:

  • Jun 2, 2026, 13:51 UTC

    ABIVAX Société Anonyme announced positive Phase III ABTECT trial results for obefazimod in ulcerative colitis.

    Source:

  • Jun 2, 2026, 08:45 UTC

    Abivax reported adverse events in a late-stage clinical trial for its bowel-disease drug, with some patients developing cancer unrelated to the treatment.

    Source:

  • Jun 2, 2026, 08:21 UTC

    Abivax shares tumbled after the company reported late-stage data for its experimental inflammatory bowel drug, with investors focusing on safety concerns.

    Source: